NEW YORK, N.Y. – May 11, 2026 – ICR, one of the largest independent strategic communications and advisory firms in North America, today announced the appointment of Jim Weiss, founder and Chairman of Real Chemistry, to its Board of Directors.
Over two decades, Mr. Weiss built Real Chemistry into a 2,000+-person organization focused on helping clients navigate the complexities of bringing scientific advances to market. In doing so, he established himself as one of the most consequential firm-builders in the industry, operating at the intersection of life sciences, creativity, and innovation.
ICR combines capital markets expertise with communications advisory to help companies and leaders drive value in the public arena. The firm’s integrated service model — pairing former Wall Street analysts with senior communications professionals — has fueled rapid growth as the close combination of capital markets expertise and communications strategy becomes a definitive competitive advantage.
“Throughout his career, Jim has made a name for himself as an innovator, connector, and operator. His expertise scaling Real Chemistry from zero to over $600M in revenue will provide essential guidance as we enter our next phase of growth,” said ICR Chairman Tom Ryan. “Jim’s first-hand knowledge of what it takes to build, attract talent, and win in a competitive market is exactly what we need as we push into our next chapter. We’re delighted to have him on our board.”
“ICR has built something genuinely differentiated in this market,” said Jim Weiss. “The combination of capital markets expertise and communications depth is a powerful model. I’m eager to help build continued momentum.”
Mr. Weiss’s appointment also reinforces ICR’s commitment to its healthcare capital markets practice, which now includes more than 80 team members serving over 150 clients across all healthcare sub-sectors globally.
“Jim has built one of this industry’s defining firms. This is not a common credential, and we don’t take it lightly,” said ICR CEO Anton Nicholas. “His perspective on what it takes to scale a complex, high-performing organization will directly shape how we think about growth across the firm.”
Mr. Weiss founded Real Chemistry (originally W2O Group) in 2001 and served as CEO until 2022, when he transitioned to chairman. He began his career at Genentech during its formative commercial years and went on to hold senior roles at Sanofi and medical device company Heartport before launching his own firm. A 2025 PRWeek Hall of Fame inductee and member of the Syracuse University Newhouse School of Public Communications Hall of Fame, Mr. Weiss also serves on the boards of Walker Sands and Dstillery. He also serves as an advisor and/or board member to a number of nonprofit organizations, including the Foundation for the National Institutes of Health, Healthcare Businesswomen’s Association and the Cancer Research Institute. He is an executive advisor of New Mountain Capital, which took a majority stake in Real Chemistry in 2019. He holds a degree from the S.I. Newhouse School of Public Communications at Syracuse University and was recently named a Newhouse Professor in Residence. His podcast, Get Real with Jim Weiss, can be followed on YouTube and other platforms.
